SNS-032 (BMS-387032) is a cyclin-dependent kinase 2 (CDK2), 7, and 9 inhibitor under pre-clinical and clinical investigation for a wide range of solid and hematologic malignancies [3–16] including neuroblastoma [17–19]. This evidence concerns the gene CDK2 and neuroblastoma.